Close

Mizuho Securities Starts Jazz Pharmaceuticals (JAZZ) at Buy

October 8, 2015 4:35 PM EDT
Get Alerts JAZZ Hot Sheet
Price: $120.42 -0.07%

Rating Summary:
    31 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE

Mizuho Securities initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price target of $164.00.

Analyst Irina Koffler commented, "JAZZ had a lackluster trading year due to the generic overhang on its key revenue driver, Xyrem. However, the stock now appears undervalued even when we account for generic risk. Jazz has the highest operating margins in our coverage universe, assets that should be relatively shielded from Medicare pricing pressure, a strong pipeline, an attractive balance sheet, and a low Irish tax rate. We believe that these characteristics could make Jazz an eventual takeout target once its Xyrem litigation is resolved."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $130.94 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage